These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

148 related items for PubMed ID: 10499644

  • 1. Regional treatment of epidermal growth factor receptor vIII-expressing neoplastic meningitis with a single-chain immunotoxin, MR-1.
    Archer GE, Sampson JH, Lorimer IA, McLendon RE, Kuan CT, Friedman AH, Friedman HS, Pastan IH, Bigner DD.
    Clin Cancer Res; 1999 Sep; 5(9):2646-52. PubMed ID: 10499644
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis.
    Bigner DD, Archer GE, McLendon RE, Friedman HS, Fuchs HE, Pai LH, Herndon JE, Pastan IH.
    Clin Cancer Res; 1995 Dec; 1(12):1545-55. PubMed ID: 9815955
    [Abstract] [Full Text] [Related]

  • 3. Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals.
    Engebraaten O, Hjortland GO, Juell S, Hirschberg H, Fodstad O.
    Int J Cancer; 2002 Feb 20; 97(6):846-52. PubMed ID: 11857366
    [Abstract] [Full Text] [Related]

  • 4. Cytotoxic and antitumor activity of a recombinant immunotoxin composed of disulfide-stabilized anti-Tac Fv fragment and truncated Pseudomonas exotoxin.
    Reiter Y, Kreitman RJ, Brinkmann U, Pastan I.
    Int J Cancer; 1994 Jul 01; 58(1):142-9. PubMed ID: 8014011
    [Abstract] [Full Text] [Related]

  • 5. Construction, expression, and activity of a novel immunotoxin comprising a humanized antiepidermal growth factor receptor scFv and modified Pseudomonas aeruginosa exotoxin A.
    Akbari B, Farajnia S, Zarghami N, Mahdieh N, Rahmati M, Khosroshahi SA, Barzegar A, Rahbarnia L.
    Anticancer Drugs; 2017 Mar 01; 28(3):263-270. PubMed ID: 27861173
    [Abstract] [Full Text] [Related]

  • 6. In vivo efficacy of intrathecal transferrin-Pseudomonas exotoxin A immunotoxin against LOX melanoma.
    Hall WA, Myklebust A, Godal A, Nesland JM, Fodstad O.
    Neurosurgery; 1994 Apr 01; 34(4):649-55; discussion 655-6. PubMed ID: 8008162
    [Abstract] [Full Text] [Related]

  • 7. Recombinant anti-EGFR immunotoxin 425(scFv)-ETA' demonstrates anti-tumor activity against disseminated human pancreatic cancer in nude mice.
    Bruell D, Bruns CJ, Yezhelyev M, Huhn M, Müller J, Ischenko I, Fischer R, Finnern R, Jauch KW, Barth S.
    Int J Mol Med; 2005 Feb 01; 15(2):305-13. PubMed ID: 15647848
    [Abstract] [Full Text] [Related]

  • 8. An epidermal growth factor receptor-targeting immunotoxin based on IgG shows potent antitumor activity against head and neck cancer.
    Huang M, Park J, Seo J, Ko S, Yang YH, Lee Y, Kim HJ, Lee BS, Lee YS, Ko BJ, Jung ST, Park D, Yoo TH, Kim CH.
    FASEB J; 2024 Jul 15; 38(13):e23759. PubMed ID: 38949635
    [Abstract] [Full Text] [Related]

  • 9. Immunotoxins with increased activity against epidermal growth factor receptor vIII-expressing cells produced by antibody phage display.
    Beers R, Chowdhury P, Bigner D, Pastan I.
    Clin Cancer Res; 2000 Jul 15; 6(7):2835-43. PubMed ID: 10914732
    [Abstract] [Full Text] [Related]

  • 10. Anti-Tac(Fab)-PE40, a recombinant double-chain immunotoxin which kills interleukin-2-receptor-bearing cells and induces complete remission in an in vivo tumor model.
    Kreitman RJ, Chang CN, Hudson DV, Queen C, Bailon P, Pastan I.
    Int J Cancer; 1994 Jun 15; 57(6):856-64. PubMed ID: 8206679
    [Abstract] [Full Text] [Related]

  • 11. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity.
    Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ, FitzGerald DJ, Pastan I.
    Blood; 2009 Apr 16; 113(16):3792-800. PubMed ID: 18988862
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins.
    Wels W, Beerli R, Hellmann P, Schmidt M, Marte BM, Kornilova ES, Hekele A, Mendelsohn J, Groner B, Hynes NE.
    Int J Cancer; 1995 Jan 03; 60(1):137-44. PubMed ID: 7814146
    [Abstract] [Full Text] [Related]

  • 15. Systemic immunotoxin treatment inhibits formation of human breast cancer metastasis and tumor growth in nude rats.
    Engebraaten O, Sivam G, Juell S, Fodstad O.
    Int J Cancer; 2000 Dec 15; 88(6):970-6. PubMed ID: 11093823
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys.
    Kreitman RJ, Wang QC, FitzGerald DJ, Pastan I.
    Int J Cancer; 1999 Mar 31; 81(1):148-55. PubMed ID: 10077166
    [Abstract] [Full Text] [Related]

  • 18. The recombinant immunotoxin anti-Tac(Fv)-Pseudomonas exotoxin 40 is cytotoxic toward peripheral blood malignant cells from patients with adult T-cell leukemia.
    Kreitman RJ, Chaudhary VK, Waldmann T, Willingham MC, FitzGerald DJ, Pastan I.
    Proc Natl Acad Sci U S A; 1990 Nov 31; 87(21):8291-5. PubMed ID: 2236041
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.